HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Inc. has entered an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a second-generation multi-cytokine fusion molecule reagent used to produce highly functional human CAR-T cells. The reagent shows superior preclinical results, potentially improving CAR-T cell potency, longevity, and reducing manufactur…